Literature DB >> 30131377

TLR2 Promotes Glioma Immune Evasion by Downregulating MHC Class II Molecules in Microglia.

Jiawen Qian1,2, Feifei Luo2,3, Jiao Yang1,2, Jun Liu1, Ronghua Liu1, Luman Wang1, Chen Wang1,2, Yuting Deng1,2, Zhou Lu1, Yuedi Wang1,2, Mingfang Lu1, Ji-Yang Wang1, Yiwei Chu4,2.   

Abstract

Gliomas, the most common primary neoplasms in the brain, are notorious for their ability to evade the immune response. Despite microglial infiltration in gliomas, expression of MHC class II molecules in those microglia is compromised. Here, we report that Toll-like receptor 2 (TLR2) activation downregulated expression of MHC class II molecules in microglia in an orthotopic murine glioma model. TLR2-induced microglial impairment hindered the proliferation and activation of CD4+ T cells, which facilitated glioma immune evasion. TLR2-induced downregulation of MHC class II molecules was caused by suppression of the master regulator of MHC class II molecule transcription, Ciita TLR2 activation triggered downstream MAPK/ERK1/2 signaling and loss of histone H3 acetylation at Ciita promoters, which in turn inhibited Ciita expression. In glioblastoma tissues, various endogenous TLR2 ligands, including the heat shock proteins that are endogenous TLR2 ligands, were upregulated, a response that correlated with CIITA inhibition. Thus, TLR2 promotes glioma immune-system evasion. These results advance our understanding of microglia as antigen-presenting cells in the context of glioma. In the glioma tumor microenvironment, TLR2 activation of microglia induces downregulation of microglial MHC class II expression. Impaired MHC class II expression limits T-cell-dependent antitumor immunity. Cancer Immunol Res; 6(10); 1220-33. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30131377     DOI: 10.1158/2326-6066.CIR-18-0020

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  31 in total

1.  Peptidoglycan-treated tumor antigen-pulsed dendritic cells impart complete resistance against tumor rechallenge.

Authors:  A Patidar; S Selvaraj; P Chauhan; C A Guzman; T Ebensen; A Sarkar; D Chattopadhyay; B Saha
Journal:  Clin Exp Immunol       Date:  2020-06-26       Impact factor: 4.330

2.  Deletion of the RNA regulator HuR in tumor-associated microglia and macrophages stimulates anti-tumor immunity and attenuates glioma growth.

Authors:  Jiping Wang; Jianmei W Leavenworth; Anita B Hjelmeland; Reed Smith; Neha Patel; Ben Borg; Ying Si; Peter H King
Journal:  Glia       Date:  2019-08-10       Impact factor: 7.452

Review 3.  The versatile role of HuR in Glioblastoma and its potential as a therapeutic target for a multi-pronged attack.

Authors:  Abhishek Guha; Saboora Waris; Louis B Nabors; Natalia Filippova; Myriam Gorospe; Thaddaeus Kwan; Peter H King
Journal:  Adv Drug Deliv Rev       Date:  2021-12-16       Impact factor: 15.470

Review 4.  Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma.

Authors:  Lizhi Pang; Fatima Khan; Amy B Heimberger; Peiwen Chen
Journal:  Trends Cancer       Date:  2022-05-24

5.  A distinct microglial subset at the tumor-stroma interface of glioma.

Authors:  Michael D Caponegro; Ki Oh; Miguel M Madeira; Daniel Radin; Nicholas Sterge; Maryam Tayyab; Richard A Moffitt; Stella E Tsirka
Journal:  Glia       Date:  2021-03-11       Impact factor: 7.452

6.  Glioma-Associated Stromal Cells Stimulate Glioma Malignancy by Regulating the Tumor Immune Microenvironment.

Authors:  Xiangming Cai; Feng Yuan; Junhao Zhu; Jin Yang; Chao Tang; Zixiang Cong; Chiyuan Ma
Journal:  Front Oncol       Date:  2021-04-29       Impact factor: 6.244

7.  Construction of Molecular Subtypes and Related Prognostic and Immune Response Models Based on M2 Macrophages in Glioblastoma.

Authors:  Kai Xiao; Shushan Zhao; Jian Yuan; Yimin Pan; Ya Song; Lanhua Tang
Journal:  Int J Gen Med       Date:  2022-01-26

8.  GNG5 is a novel oncogene associated with cell migration, proliferation, and poor prognosis in glioma.

Authors:  Wang Zhang; Zhendong Liu; Binchao Liu; Miaomiao Jiang; Shi Yan; Xian Han; Hong Shen; Meng Na; Yanbiao Wang; Zhishuai Ren; Binfeng Liu; Zhenfeng Jiang; Yanzheng Gao; Zhiguo Lin
Journal:  Cancer Cell Int       Date:  2021-06-07       Impact factor: 5.722

9.  Reprogramming the immunosuppressive microenvironment of IDH1 wild-type glioblastoma by blocking Wnt signaling between microglia and cancer cells.

Authors:  Dandan Fan; Qi Yue; Jian Chen; Cong Wang; Ruilin Yu; Ziyi Jin; Shujie Yin; Qinyue Wang; Luo Chen; Xueling Liao; Chengyuan Peng; Jianpin Zhang; Zhonglian Cao; Ying Mao; Ruimin Huang; Liang Chen; Cong Li
Journal:  Oncoimmunology       Date:  2021-06-06       Impact factor: 8.110

10.  CD206 Expression in Induced Microglia-Like Cells From Peripheral Blood as a Surrogate Biomarker for the Specific Immune Microenvironment of Neurosurgical Diseases Including Glioma.

Authors:  Shunya Tanaka; Masahiro Ohgidani; Nobuhiro Hata; Shogo Inamine; Noriaki Sagata; Noritoshi Shirouzu; Nobutaka Mukae; Satoshi O Suzuki; Hideomi Hamasaki; Ryusuke Hatae; Yuhei Sangatsuda; Yutaka Fujioka; Kosuke Takigawa; Yusuke Funakoshi; Toru Iwaki; Masako Hosoi; Koji Iihara; Masahiro Mizoguchi; Takahiro A Kato
Journal:  Front Immunol       Date:  2021-06-29       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.